Q2 FY2026 EarningsQ2 FY2026 results exceeded consensus on the top line, with revenue of $219.1M vs. $205.4M expected (+6.6%), driven by a 52% YoY surge in core growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO). However, profitability metrics missed significantly due to a $54.9M non-cash impairment charge on APOKYN and rising SG&A costs. Management raised FY2026 revenue guidance to $860M–$890M and announced a strategic merger of equals with Indivior Pharmaceuticals.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Supernus Pharma(SUPN) the Revenue is 219.06 M (+32.4%), Beat estimate;the EBIT is 31.2 M (-23.72%), Beat estimate;the EPS is -1.01 (-352.5%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.22B32.40%
0.21B24.16%
+0.01B8.24%
EBITExceed expectations
0.03B23.72%
0.03B31.95%
+0.00B8.23%
EPSMiss expectations
-1.01352.50%
0.03591.25%
-1.0450261.25%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf